397 related articles for article (PubMed ID: 32629016)
1. Clinical use of biologics for asthma treatment by allergy specialists: A questionnaire survey.
Kuruvilla M; Ariue B; Oppenheimer JJ; Singh U; Bernstein JA
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):433-439. PubMed ID: 32629016
[TBL] [Abstract][Full Text] [Related]
2. Choice of biologics in asthma endotypes.
Wangberg H; Woessner K
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
[TBL] [Abstract][Full Text] [Related]
3. How Frequently Is Asthma Objectively Demonstrated before Starting a Biologic? Quality Assessment of a Group Practice of Allergists and Immunologists.
Dziewa I; Craig T; Al-Shaikhly T
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33352823
[TBL] [Abstract][Full Text] [Related]
4. Home Self-Administration of Biologics - A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians.
Timmermann H; Mailänder C
Pneumologie; 2020 Feb; 74(2):103-111. PubMed ID: 31935761
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
6. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
Weheba IM; Abdelsayed AM; Arnaout RK; Zeitouni MO; Mobaireek KF; AlHarthi TB; Mobeireek AF
Ann Saudi Med; 2018; 38(6):439-444. PubMed ID: 30531179
[TBL] [Abstract][Full Text] [Related]
8. Strategies for choosing a biologic for your patient with allergy or asthma.
Saco T; Ugalde IC; Cardet JC; Casale TB
Ann Allergy Asthma Immunol; 2021 Dec; 127(6):627-637. PubMed ID: 34642091
[TBL] [Abstract][Full Text] [Related]
9. Asthma biologics: Underuse, overuse, and best use?
Rank MA; Oppenheimer JJ
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):358-359. PubMed ID: 30578858
[No Abstract] [Full Text] [Related]
10. Controversies and opportunities in severe asthma.
Humbert M; Busse W; Hanania NA
Curr Opin Pulm Med; 2018 Jan; 24(1):83-93. PubMed ID: 29059087
[TBL] [Abstract][Full Text] [Related]
11. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
[TBL] [Abstract][Full Text] [Related]
12. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
13. Biologics and biomarkers for asthma, urticaria, and nasal polyposis.
Casale TB
J Allergy Clin Immunol; 2017 May; 139(5):1411-1421. PubMed ID: 28477720
[TBL] [Abstract][Full Text] [Related]
14. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
[No Abstract] [Full Text] [Related]
15. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
[TBL] [Abstract][Full Text] [Related]
16. Insights from the trends of omalizumab and mepolizumab utilization in patients with asthma: A population-based cohort study using the National Database in Japan.
Kan-O K; Noda T; Ogata H; Masaki K; Nishioka Y; Myojin T; Adachi T; Morita H; Imamura T; Tamari M; Kainuma K;
Respir Investig; 2024 Jan; 62(1):113-120. PubMed ID: 38101278
[TBL] [Abstract][Full Text] [Related]
17. Prospects for new and emerging therapeutics in severe asthma: the role of biologics.
Kepil Özdemir S; Bavbek S
Expert Rev Respir Med; 2017 Jun; 11(6):505-512. PubMed ID: 28464704
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
Anderson WC; Szefler SJ
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
[TBL] [Abstract][Full Text] [Related]
19. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy.
Nagase H; Suzukawa M; Oishi K; Matsunaga K
Allergol Int; 2023 Jan; 72(1):11-23. PubMed ID: 36543689
[TBL] [Abstract][Full Text] [Related]
20. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
Moore WC; Panettieri RA; Trevor J; Ledford DK; Lugogo N; Soong W; Chipps BE; Carr W; Belton L; Gandhi H; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):294-303.e1. PubMed ID: 32304877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
